medigraphic.com
ISSN 1561-3186 (Electronic)

2019, Number 2

<< Back Next >>

Rev Acta Médica 2019; 20 (2)

Cardiovascular risk in patients with rheumatoid arthritis

Chico CA, Uguña SF, Estévez TM, Rodríguez LM, Hidalgo CT

Language: Spanish
References: 22
Page: 1-13
PDF size: 284.50 Kb.


ABSTRACT

Introduction: As a result of the interaction between traditional cardiovascular risk factors and those associated with the state of systemic inflammation, rheumatoid arthritis may cause risk for the development of cardiovascular diseases.
Objective: To describe cardiovascular risk factors and their impact on cardiovascular risk in patients with rheumatoid arthritis.
Methods: An observational, descriptive, cross-sectional study that included 200 patients diagnosed with rheumatoid arthritis and studied between July 2015 and December 2016. The traditional and nontraditional cardiovascular risk factors were recorded as variables. Patients with a diagnosis of previous cardiovascular disease were excluded.
Results: There was a predominance of the female sex (90.0%), average age of 56.9 years ± 10.4 with evolution time of 9.6 years ± 8.6. The most frequent traditional risk factors were arterial hypertension (54.0%) and overweight (38.5%), while the nontraditional ones were positive rheumatoid factor (70.0%), moderate to high disease activity score of 28 joints C-reactive protein (DAS28-CRP) (58.0%), and evolution time greater than 10 years (33.0%). The Framingham 10-year cardiovascular risk score was low in 62.5% and moderate to high in 37.5%. Arterial hypertension, diabetes mellitus, dyslipidemia and smoking were associated with moderate to high cardiovascular risk (p< 0.05).
Conclusions: Most of the patients with rheumatoid arthritis presented low cardiovascular risk and there was an association between some traditional cardiovascular risk factors regarding moderate and high cardiovascular risk.


REFERENCES

  1. Smolen JS, Aletaha D, Mclnnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. PubMed: PMID: 27156434.

  2. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693-704. PubMed: PMID:26282082.

  3. Houri Levi E, Watad A, Whitby A, Tiosano S, Comaneshter D, Cohen AD, et al. Coexistence of ischemic heart disease and rheumatoid arthritis patients - a case control study. Autoimmun Rev. 2016;15(4):396-6. PubMed: PMID: 26808075.

  4. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta - analysis. PLoS One. 2015;10(2):e01117952. PubMed: PMID: 25689371.

  5. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12(10):1004-15.

  6. Nagy G, Nemeth N, Buzas EI. Mechanisms of vascular comorbidity in autoimmune diseases. Curr Opion Rheumatol 2018;30:197-206. PubMed.PMID:29256898.

  7. Ong KL, Wu BJ, Cheung BMY, Barter PJ, Rye KA. Arthritis: Its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Ann Epidemiol 2013;23(2):80-6.

  8. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for cardiovascular prevention and rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. PubMed: PMID:27222591.

  9. Balsa A, Lojo Oliveira L, Alperi Lopez M, García Manrique M, Ordonez Canizares C, Pérez L, et al. Prevalence of comorbidities in Rheumatoid Arthritis and evolution of their monitoring in clinical practice: The Spanish cohort of the COMORA study. Rheumatol Clin. 2019 [acceso: 20/02/2018];15(2):102-8. Disponible en: https://www.reumatologiaclinica. org/es-prevalence-comorbidities-in-rheumatoid-arthritis-articulo-S1699258X17301341

  10. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-8.

  11. Nurmohamed M, Dijkmans B. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68:453-5.

  12. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745-57. PubMed: PMID:26647358.

  13. Jagpal A, Millan Navarro I. Cardiovascular co-morbidity in patients with rheumatoid arthritis:a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatology. 2018;2(10):1-14. PubMed: PMID:30886961.

  14. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(7):1301-8.

  15. Liao KP, Diogo D, Cui J, Cai T, Okada Y, Gainer VS, et al. Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls. Ann Rheum Dis. 2014;73(6):1170-5.

  16. Robertson J, Peters MJ, Mclnnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 2013;9(9):513-23.

  17. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol. 2009;36(6):1180-7.

  18. Ljung L, Rantapaa Dahlqvist S, Jacobsson LT, Askling J. Response to biological treatment and subsequent risk coronay events in rheumatoid arthritis. Ann Rheum Dis. 2016;75(12):2087-94. PubMed: PMID:26984007.

  19. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients a population-based cohort study. Arthritis Rheuma. 2008;58(8):2268-74.

  20. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994;93(6):2379-86.

  21. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrol LR, et al. Disease activity in rheumatoid arthritis and the risk ordiovascular events. Arthritis Rheum. 2015;67(6):1449-55. PubMed: PMID:25776112.

  22. Arts EE, Fransen J, Den Broeder AA, Van PLCM R, Popa CD. Low disease activity reduces the risk of first cardiovascular event in rheumatoid arthritis: a time- dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76(10):163-9. PubMed: PMID:28606965.




2020     |     www.medigraphic.com